The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
Open accessAbstract
BACKGROUND: ¹⁸F-FDFG uptake by brain tissue as measured by positron emission tomography (PET) is a well-established method for assessment of brain function in people with dementia. Certain findings on brain PET scans can potentially predict the decline of mild cognitive Impairment (MCI) to Alzheimer's disease dementia or other dementias. OBJECTIVES: To determine the diagnostic accuracy of the ¹⁸F-FDG PET index test for detecting people with MCI at baseline who would clinically convert to Alzheimer's disease dementia or other forms of dementia at follow-up. SEARCH METHODS: We searched the Cochrane Register of Diagnostic Test Accuracy Studies, MEDLINE, EMBASE, Science Citation Index, PsycINFO, BIOSIS previews, LILACS, MEDION, (Meta-analyses van Diagnostisch Onderzoek), DARE (Database of Abstracts of Reviews of Effects), HTA (Health Technology Assessment Database), ARIF (Aggressive Research Intelligence Facility) and C-EBLM (International Federation of Clinical Chemistry and Laboratory Medicine Committee for Evidence-based Laboratory Medicine) databases to January 2013. We checked the reference lists of any relevant studies and systematic reviews for additional studies. SELECTION CRITERIA: We included studies that evaluated the diagnostic accuracy of ¹⁸F-FDG PET to determine the conversion from MCI to Alzheimer's disease dementia or to other forms of dementia, i.e. any or all of vascular dementia, dementia with Lewy bodies, and fronto-temporal dementia. These studies necessarily employ delayed verification of conversion to dementia and are sometimes labelled as 'delayed verification cross-sectional studies'. DATA COLLECTION AND ANALYSIS: Two blinded review authors independently extracted data, resolving disagreement by discussion, with the option to involve a third review author as arbiter if necessary. We extracted and summarised graphically the data for two-by-two tables. We conducted exploratory analyses by plotting estimates of sensitivity and specificity from each study on forest plots and in receiver operating characteristic (ROC) space. When studies had mixed thresholds, we derived estimates of sensitivity and likelihood ratios at fixed values (lower quartile, median and upper quartile) of specificity from the hierarchical summary ROC (HSROC) models. MAIN RESULTS: We included 14 studies (421 participants) in the analysis. The sensitivities for conversion from MCI to Alzheimer's disease dementia were between 25% and 100% while the specificities were between 15% and 100%. From the summary ROC curve we fitted we estimated that the sensitivity was 76% (95% confidence interval (CI): 53.8 to 89.7) at the included study median specificity of 82%. This equates to a positive likelihood ratio of 4.03 (95% CI: 2.97 to 5.47), and a negative likelihood ratio of 0.34 (95% CI: 0.15 to 0.75). Three studies recruited participants from the same Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort but only the largest ADNI study (Herholz 2011) is included in the meta-analysis. In order to demonstrate whether the choice of ADNI study or discriminating brain region (Chételat 2003) or reader assessment (Pardo 2010) make a difference to the pooled estimate, we performed five additional analyses. At the median specificity of 82%, the estimated sensitivity was between 74% and 76%. There was no impact on our findings. In addition to evaluating Alzheimer's disease dementia, five studies evaluated the accuracy of ¹⁸F-FDG PET for all types of dementia. The sensitivities were between 46% and 95% while the specificities were between 29% and 100%; however, we did not conduct a meta-analysis because of too few studies, and those studies which we had found recruited small numbers of participants. Our findings are based on studies with poor reporting, and the majority of included studies had an unclear risk of bias, mainly for the reference standard and participant selection domains. According to the assessment of Index test domain, more than 50% of studies were of poor methodological quality. AUTHORS' CONCLUSIONS: It is difficult to determine to what extent the findings from the meta-analysis can be applied to clinical practice. Given the considerable variability of specificity values and lack of defined thresholds for determination of test positivity in the included studies, the current evidence does not support the routine use of ¹⁸F-FDG PET scans in clinical practice in people with MCI. The ¹⁸F-FDG PET scan is a high-cost investigation, and it is therefore important to clearly demonstrate its accuracy and to standardise the process of ¹⁸F-FDG PET diagnostic modality prior to its being widely used. Future studies with more uniform approaches to thresholds, analysis and study conduct may provide a more homogeneous estimate than the one available from the included studies we have identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Research works printed but not linked: 97
- Anchisi, 2005, Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease, Archives of Neurology, 62, 1728, 10.1001/archneur.62.11.1728 · DOI · Paper page
- Chételat, 2003, Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?, Neurology, 60, 1374, 10.1212/01.WNL.0000055847.17752.E6 · DOI · Paper page
- Clerici, 2009, Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis, Quarterly Journal of Nuclear Medicine and Molecular Imaging, 53, 646
- Drzezga, 2005, Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET, Journal of Nuclear Medicine, 46, 1625
- Fellgiebel, 2007, FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment, Psychiatry Research, 155, 167, 10.1016/j.pscychresns.2006.12.002 · DOI
- Galluzzi, 2010, The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment, Journal of Neurology, 257, 2004-14, 10.1007/s00415-010-5650-0 · DOI
- Herholz, 2011, Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment, Journal of Nuclear Medicine, 52, 1218, 10.2967/jnumed.111.090902 · DOI
- Mosconi, 2004, MCI conversion to dementia and APOE genotype: a prediction study with FDG-PET, Neurology, 63, 2332, 10.1212/01.WNL.0000147469.18313.3B · DOI · Paper page
- Nobili, 2008, Principal component analysis of FDG PET in amnestic MCI, European Journal of Nuclear Medicine and Molecular Imaging, 35, 2191, 10.1007/s00259-008-0869-z · DOI
- Ossenkoppele, 2012, Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET, European Journal of Nuclear Medicine and Molecular Imaging, 39, 990, 10.1007/s00259-012-2102-3 · DOI · Paper page
- Pardo, 2010, Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years, Alzheimer's & Dementia, 6, 326, 10.1016/j.jalz.2009.09.005 · DOI
- Schmand, 2012, Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment, Journal of Alzheimer's Disease, 29, 641, 10.3233/JAD-2012-111703 · DOI
- Bastin C Kerrouche N Lekeu F Adam S Guillame B Lemaire C Controlled memory processes in questionable Alzheimer's disease: A view from neuroimaging research Journal of Alzheimer's Disease 2010 547 60 · DOI
- Beckett LA Harvey DJ Gamst A Donohue M Kornak J Zhang H The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes Alzheimer's & Dementia 2010 257 64 · DOI
- Charil A Carbonell F Reilhac A Deduck K Sood R Evans A Changes in MRI cortical thickness and [18F]FDG PET data over 24 months in subjects from the Alzheimer's disease neuroimaging initiative (ADNI) study Alzheimer's and Dementia Conference: Alzheimer's Association International Conference, AAIC 11 Paris France. Conference Publication 2011 · doi:10.1016/j.jalz.2011.05.583
- Chen K Langbaum JB Fleisher AS Ayutyanont N Reschke C Lee W Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative NeuroImage 2010 654 64 · DOI · Paper page
- Chételat, 2001, Metabolic profile of patients with mild cognitive impairment (MCI) destined to convert to Alzheimer's disease (AD), Society for Neuroscience Abstracts, 27, 196
- Chételat G Eustache F Viader F De la Sayette V Pélerin A Mézenge F FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment Neurocase 2005 14 25 · DOI · Paper page
- Desikan RS Cabral HJ Settecase F Hess CP Dillon WP Glastonbury CM Automated MRI measures predict progression to Alzheimer's disease Neurobiology of Aging 2010 1364 74 · DOI
- Drzezga, 2003, Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study, European Journal of Nuclear Medicine and Molecular Imaging, 30, 1104, 10.1007/s00259-003-1194-1 · DOI · Paper page
- Forsberg A Engler H Almkvist O Blomquist G Hagman G Wall A PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiology of Aging 2008 1456 65 · DOI · Paper page
- Gray, 2012, Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer's disease, NeuroImage, 60, 221, 10.1016/j.neuroimage.2011.12.071 · DOI · Paper page
- Ishii, 2009, Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project, International Psychogeriatrics, 21, 148, 10.1017/S1041610208008132 · DOI
- Ishii K Ito K Senda M Kato T Fukuyama H Ouchi Y Meguro K et al. SEAD-J Group FDG-PET and automatic diagnosis systems for prediction of conversion to Alzheimer disease in subjects with mild cognitive impairments: Study on diagnosis of early Alzheimer disease-Japan (SEAD-J) Annual Congress of the European Association of Nuclear Medicine, Birmingham. Conference Publication 2011
- Jagust, 2007, What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?, Neurology, 69, 871, 10.1212/01.wnl.0000269790.05105.16 · DOI · Paper page
- Kadir, 2012, Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease, Neurobiology of Aging, 33, 198.e1, 10.1016/j.neurobiolaging.2010.06.015 · DOI
- Kawashima, 2012, Inclusion criteria provide heterogeneity in baseline profiles of patients with mild cognitive impairment: comparison of two prospective cohort studies, BMJ Open, 2, e000773, 10.1136/bmjopen-2011-000773 · DOI
- Kim, 2010, Comparison of neuropsychological and FDG-PET findings between early- versus late-onset mild cognitive impairment: A five-year longitudinal study, Dementia and Geriatric Cognitive Disorders, 29, 213, 10.1159/000278422 · DOI
- Landau, 2011, Associations between cognitive, functional, and FDG-PET measures of decline in AD and MC, Neurobiology of Aging, 32, 1207, 10.1016/j.neurobiolaging.2009.07.002 · DOI · Paper page
- Landau, 2012, Amyloid deposition, hypometabolism, and longitudinal cognitive decline, Annals of Neurology, 72, 578, 10.1002/ana.23650 · DOI · Paper page
- Lee, 2011, Combination of cerebral metabolic and cognitive information as a better predictor of the conversion to Alzheimer's disease in mild cognitive impairment: A two-year follow-up study, Alzheimer's & Dementia, 7, S29
- Lo, 2011, Longitudinal change of biomarkers in cognitive decline, Archives of Neurology, 68, 1257, 10.1001/archneurol.2011.123 · DOI · Paper page
- Lorenzi, 2010, Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment, Neurobiology, 31, 1443
- Lucidi G Marini S Nacmias B Berti V Bessi V Bracco L et al . Journal of Alzheimer's Disease Conference: 7th Congresso Sindem: Italian Association for the Study of Dementia Linked to the Italian Neurological Society SIN Naples Italy Multidisciplinary approach to MCI help to evaluate risk of conversion in AD Journal of Alzheimer's Disease Conference: 7th Congresso Sindem: Italian Association for the Study of Dementia Linked to the Italian Neurological Society, SIN Naples Italy 2012 (var.pagings)
- Morbelli, 2010, Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study, European Journal of Nuclear Medicine and Molecular Imaging, 37, 36, 10.1007/s00259-009-1218-6 · DOI
- Morbelli, 2012, Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project, Neurobiology of Aging, 33, 2533, 10.1016/j.neurobiolaging.2012.01.005 · DOI
- Pagani, 2010, MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings, Current Alzheimer Research, 7, 287, 10.2174/156720510791162368 · DOI
- Small, 1995, Predictors of cognitive change in middle-aged and older adults with memory loss, American Journal of Psychiatry, 152, 1757, 10.1176/ajp.152.12.1757 · DOI
- Torosyan N Mason K Dahlbom M Silverman DH Predictive value of FDG-PET scans for conversion from mild cognitive impairment to dementia by subjects participating in the Alzheimer’s Disease Neuroimaging Initiative study, using a metabolic index generated with clinically routine software Molecular Imaging and Biology Conference: 2011 World Molecular Imaging Congres, San Diego, CA United States. Conference Publication 2011
- Walhovd, 2010, Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease, AJNR: American Journal of Neuroradiology, 31, 347, 10.3174/ajnr.A1809 · DOI · Paper page
- Zhang, 2012, Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers, PLoS One, 7, e33182, 10.1371/journal.pone.0033182 · DOI · Paper page
- American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)
- American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)
- Ballard, 2011, Alzheimer's disease, Lancet, 377, 1019, 10.1016/S0140-6736(10)61349-9 · DOI · Paper page
- Bartenstein, 1997, Quantitative assessment of cerebral blood flow in patients with Alzheimer’s disease by SPECT, Journal of Nuclear Medicine, 38, 1095-101
- Bartenstein, 2002, European Association of Nuclear Medicine procedure guidelines for brain imaging using [18F]FDG, European Journal of Nuclear Medicine and Molecular Imaging, 29, BP43-8
- Beynon, 2013, Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE, Cochrane Database of Systematic Reviews, 10.1002/14651858.MR000022.pub3 · DOI
- Bohnen, 2012, Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature, Journal of Nuclear Medicine, 53, 59, 10.2967/jnumed.111.096578 · DOI · Paper page
- Bossuyt PM Leeflang MM Developing criteria for including studies. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Chapter 6. Version 0.4 srdta.cochrane.org/sites/srdta.cochrane.org/files/uploads/Chapter06-Including-Studies%20%28September-2008%29.pdf 2008
- Boxer AL Miller BL Clinical features of frontotemporal dementia Alzheimer Disease and Associated Disorders 2005 S3 6 · DOI
- Bruscoli M Lovestone S Is MCI really just early dementia? A systematic review of conversion studies International Psychogeriatrics 2004 129 40 · DOI · Paper page
- Brück, 2013, [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment, European Journal of Nuclear Medicine and Molecular Imaging, 40, 1567, 10.1007/s00259-013-2478-8 · DOI
- Catana, 2012, PET/MRI for neurologic applications, Journal of Nuclear Medicine, 53, 1916, 10.2967/jnumed.112.105346 · DOI · Paper page
- Crook, 1986, Report of a National Institute of Mental Health Work Group: Age associated memory impairment: proposed diagnostic criteria and measures of clinical change, Developmental Neuropsychology, 2, 261, 10.1080/87565648609540348 · DOI · Paper page
- Sole, 2008, Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG-PET study, European Journal of Nuclear Medicine and Molecular Imaging, 35, 1357, 10.1007/s00259-008-0773-6 · DOI
- Drzezga, 1999, 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis, Journal of Nuclear Medicine, 40, 737-46.
- Duara R Grady C Haxby J Sundaram M Cutler N Heston L Positron emission tomography in Alzheimer's disease Neurology 1986 879 87 · DOI · Paper page
- Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet. Neurology, 6, 734, 10.1016/S1474-4422(07)70178-3 · DOI · Paper page
- Fellgiebel, 2004, Association of elevated phospho-tau levels with Alzheimer-typical 18F-Fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment, Biological Psychiatry, 56, 279, 10.1016/j.biopsych.2004.05.014 · DOI
- Ferri CP Prince M Brayne C Brodaty H Fratiglioni L Ganguli M Global prevalence of dementia: a Delphi consensus study Lancet 2005 2112 7 · DOI · Paper page
- Frisoni, 2013, Imaging markers for Alzheimer disease: which vs how, Neurology, 81, 487, 10.1212/WNL.0b013e31829d86e8 · DOI · Paper page
- Geslani DM Tierney MC Herrmann N Szalai JP Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer’s disease Dementia and Geriatric Cognitive Disorders 2005 383 9 · DOI · Paper page
- Hampel, 2010, Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives, National Reviews. Drug Discovery, 9, 560, 10.1038/nrd3115 · DOI · Paper page
- Haxby JV Grady CL Duara R Schlageter N Berg G Rapoport SI Neocortical metabolic abnormalities precede non memory cognitive defects in early Alzheimer's-type dementia Archives of Neurology 1986 882 · DOI · Paper page
- Herholz, 1999, Impairment of neocortical metabolism predicts progression in Alzheimer’s disease, Dementia and Geriatric Cognitive Disorders, 10, 494-504, 10.1159/000017196 · DOI
- Hoffman, 2000, FDG PET imaging in patients with pathologically verified dementia, Journal of Nuclear Medicine, 41, 1920
- World Health Organization, 2006, Statistical Classification of Diseases and Related Health Problems 9th Revision (ICD-9), Hospital editio
- Ishii, 2001, Statistical brain mapping of 18F-FDG PETin Alzheimer’s disease: validation of anatomic standardization for atrophied brains, Journla of Nuclear Medicine, 42, 548 -57
- Jagust, 2010, The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core, Alzheimer's & Dementia, 6, 221, 10.1016/j.jalz.2010.03.003 · DOI · Paper page
- Jelic, 1999, Diagnostic accuracies of quantitative EEG and PET in mild Alzheimer’s disease, Alzheimer's Reports, 2, 291
- Knopman, 2005, Antemortem diagnosis of frontotemporal lobar degeneration, Annals of Neurology, 57, 480-8, 10.1002/ana.20425 · DOI · Paper page
- Knottnerus JA Van Weel C Muris JWM Evaluation of diagnostic procedures BMJ 2002 477 80 · DOI · Paper page
- Laforce, 2010, The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study, American Journal of Alzheimer's Disease and Other Dementias, 25, 324, 10.1177/1533317510363468 · DOI
- Leeflang MMG Deeks JJ Gatsonis C Bossuyt PMM Systematic reviews of diagnostic test accuracy Annals of Internal Medicine 2008 889 · DOI · Paper page
- Lucignani G Frost JF Neurochemical imaging with emission tomography: Clinical applications link.springer.com/chapter/10.1007/3-540-30005-8_2#page-1Diagnostic nuclear medicine · DOI
- Matthews FE Stephan B McKeith IG Bond J Brayne C Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? Journal of the American Geriatrics Society 2008 1424 33 · DOI · Paper page
- McKhann, 1984, Clinical diagnosis of Alzheimer's disease Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- Mosconi, 2009, FDG PET in the evaluation of mild cognitive impairment and early dementia, 49, 10.1007/978-0-387-76420-7_3 · DOI
- Moulin-Romsee, 2005, Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective, European Journal of Neurology, 12, 254, 10.1111/j.1468-1331.2004.00940.x · DOI
- Neary D Snowden JS Gustafson L Passant U Stuss D Black S Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria Neurology 1998 1546 54 · DOI · Paper page
- Nitrini R Buchpiguel C Caramelli P Bahia V Mathias S Nascimento C SPECT in Alzheimer's disease: features associated with bilateral parietotemporal hypoperfusion Acta Neurologica Scandinavica 2000 172 6 · DOI
- Patterson JC Lilien DL Takalkar A Pinkston JB Early detection of brain pathology suggestive of early AD using objective evaluation of FDG-PET scans International Journal of Alzheimer's Disease 2010 ii. 946590 10.4061/2011/946590 · DOI
- Petersen RC Doody R Kurz A Mohs RC Morris JC Rabins PV Current concepts in mild cognitive impairment Archives of Neurology 2001 1985 92 · DOI · Paper page
- Petersen, 2003, Conceptual overview, 1, 10.1093/oso/9780195123425.003.0001 · DOI
- Petersen RC Mild cognitive impairment as a diagnostic entity Journal of Internal Medicine 2004 183 94 · DOI · Paper page
- Quinn, 2014, Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010079 · DOI
- Reisberg, 1982, The Global Deterioration Scale for assessment of primary degenerative dementia, American Journal of Psychiatry, 139, 1136, 10.1176/ajp.139.9.1136 · DOI · Paper page
- Román GC Tatemichi TK Erkinjuntti T Cummings J Masdeu J Garcia JH Vascular dementia diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop Neurology 1993 250 60 · DOI · Paper page
- Rosen, 1984, A new rating scale forAlzheimer’s disease, American Journal of Psychiatry, 141, 1356-64
- Rutter CM Gatsonis CA A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations Statistics in Medicine 2001 2865 84 · DOI · Paper page
- Schroeter ML Stein T Maslowski N Neumann J Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients NeuroImage 2009 1196 206 · DOI · Paper page
- Silverman, 2002, Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits, Journal of Nuclear Medicine, 43, 253
- Silverman, 2001, Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome, JAMA, 286, 2120, 10.1001/jama.286.17.2120 · DOI · Paper page
- Silverman, 2009, Clinical interpretation of brain PET scans: performing visual assessments, providing quantifying data, and generating integrated reports, 33, 10.1007/978-0-387-76420-7_2 · doi:10.1007/978-0-387-76420-7_2
- Varrone, 2009, EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2, European Journal of Nuclear Medicine and Molecular Imaging, 36, 2103, 10.1007/s00259-009-1264-0 · DOI · Paper page
- Visser PJ Kester A Jolles J Verhey F Ten-year risk of dementia in subjects with mild cognitive impairment Neurology 2006 1201 7 · DOI · Paper page
- Vacante, 2013, The accuracy of 18FDG-PET in the early diagnosis of Alzheimer’s disease dementia and other dementias in people with MCI, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010632 · DOI
Cited by
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051
Arevalo-Rodriguez, I., Smailagic, N., Roqué i Figuls, M., Ciapponi, A., Sanchez-Perez, E., Giannakou, A., Pedraza, O. L., Bonfill Cosp, X., & Cullum, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010783.pub2 · Cited by 831
Self-citationStrategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
State of the science on mild cognitive impairment (MCI)
Anderson, N. D. (2019) · CNS Spectrums · doi:10.1017/s1092852918001347 · Cited by 541
Dementia: timely diagnosis and early intervention
Robinson, L., Tang, E., & Taylor, J.-P. (2015) · BMJ · doi:10.1136/bmj.h3029 · Cited by 503
Metadata
- Authors
- Smailagic, N., Vacante, M., Hyde, C., Martin, S., Ukoumunne, O., & Sachpekidis, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-01-28
- Volume
- 2015
- Issue
- 2
- Pages
- CD010632-CD010632
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1543528560
- Cited by
- 204
- References
- 55
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). https://app.cochat.ai/papers/10.1002/14651858.cd010632.pub2
- The paper
- Smailagic, N., Vacante, M., Hyde, C., Martin, S., Ukoumunne, O., & Sachpekidis, C. (2015). 18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd010632.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.